Home/ Stocks/ PVLA

Palvella Therapeutics, Inc. Common Stock

PVLA XNAS

$118.99 +0.15 (+0.13%) ▲ 15-min delayed

Open

$116.83

High

$120.63

Low

$116.83

Volume

22.0K

Market Cap

$1.62B

About Palvella Therapeutics, Inc. Common Stock

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 29 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$1.07M	$-15,767,000	$-1.20
FY 2025	$2.59M	$-41,715,000	$-3.71
Q3 2025	$628.0K	$-11,345,000	$-1.03
Q2 2025	$690.0K	$-9,471,000	$-0.86

Earnings & Analyst Ratings

Next Earnings: Wed, Aug 12, 2026

Calendar →

TickerDaily Coverage

Why Is Palvella Therapeutics, Inc. Common Stock (PVLA) Stock Up 36.6% Today?

Market News Alex Chen · Feb 24, 2026

Palvella Therapeutics (PVLA) stock ripped 36.6% higher today following a conference call...

View All Coverage →

Get PVLA Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Palvella Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.